Biogen’s Aducanumab: Possibly the First Viable Drug Treatment of Alzheimer’s Disease? (BBC News)


There were early hopes that the drug Aducanumab (from Biogen) might be able to slow down the build-up of amyloid protein in the brain, but trials were halted in March 2019 due to “disappointing” trial results. Subsequent re-analysis of the data has, surprisingly, indicated some benefit for patients in the earliest stages of Alzheimer’s Disease, when the drug is given at higher dosage levels.

“ …a new analysis of a larger dataset of the same studies shows that higher doses of aducanumab can provide a significant benefit to patients with early Alzheimer’s, slowing their clinical decline so they preserve more of their memory and every day living skills”.

The drug approval process in different countries could take several years and is by no means certain.

Full Text Link


Roberts, M. (2019). First drug that can slow Alzheimer’s dementia. London: BBC Health News, October 22nd 2019.

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in BBC News, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Person-Centred Care, Pharmacological Treatments, Quick Insights, Universal Interest and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.